High grade gliomas

Jeremy C Ganz1

  • 1Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.

Insights

Gamma Knife radiosurgery (GKNS) shows limited benefit for primary malignant glioma treatment. However, combining GKNS with bevacizumab may improve survival for younger patients with recurrent tumors under 4cm.

Area of Science:

  • Neurosurgery
  • Radiation Oncology
  • Oncology

Background:

  • Malignant gliomas are aggressive brain tumors with limited primary treatment options.
  • The role of Gamma Knife radiosurgery (GKNS) in glioma management is under investigation.

Purpose of the Study:

  • To evaluate the efficacy of GKNS in the primary and recurrent treatment of malignant gliomas.
  • To assess the potential survival benefits of combining GKNS with bevacizumab.

Main Methods:

  • Review of existing evidence on GKNS for malignant gliomas.
  • Analysis of outcomes in patients with recurrent tumors treated with GKNS and bevacizumab.

Main Results:

  • GKNS has minimal efficacy as a primary treatment for malignant gliomas.
  • Combined GKNS and bevacizumab therapy demonstrated potential to prolong overall survival in select patients with recurrent tumors (≤4cm, younger age).

Conclusions:

  • GKNS has a restricted role in malignant glioma management, particularly in primary settings.
  • Further research is necessary to define the optimal application of GKNS, especially in combination therapies for recurrent gliomas.

Related Concept Videos